Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations.

Tamura Y, Peng P, Liu K, Daou M, Srivastava PK.

Science. 1997 Oct 3;278(5335):117-20. Erratum in: Science 1999 Feb 19;283(5405):preceding 1119.

2.

Heat shock protein-peptide complexes in cancer immunotherapy.

Srivastava PK, Udono H.

Curr Opin Immunol. 1994 Oct;6(5):728-32. Review.

PMID:
7826528
3.

Heat shock protein--peptide complexes as immunotherapy for human cancer.

Przepiorka D, Srivastava PK.

Mol Med Today. 1998 Nov;4(11):478-84. Review.

PMID:
9857367
4.

Immunotherapy for human cancer using heat shock protein-peptide complexes.

Srivastava PK.

Curr Oncol Rep. 2005 Mar;7(2):104-8. Review.

PMID:
15717943
5.

Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity.

Calderwood SK, Theriault JR, Gong J.

Eur J Immunol. 2005 Sep;35(9):2518-27. Review.

6.

Heat shock protein gp96 and cancer immunotherapy.

Peibin Y, Shude Y, Changzhi H.

Chin Med Sci J. 2002 Dec;17(4):251-6. Review.

PMID:
12901515
7.

Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors.

Blachere NE, Srivastava PK.

Semin Cancer Biol. 1995 Dec;6(6):349-55. Review.

PMID:
8938273
8.

Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications.

Hoos A, Levey DL.

Expert Rev Vaccines. 2003 Jun;2(3):369-79. Review.

PMID:
12903802
9.

Chaperones and slow death--a recipe for tumor immunotherapy.

Calderwood SK.

Trends Biotechnol. 2005 Feb;23(2):57-9. Review.

PMID:
15661338
10.

Stress-induced proteins in immune response to cancer.

Srivastava PK, Maki RG.

Curr Top Microbiol Immunol. 1991;167:109-23. Review.

PMID:
1711433
11.

Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.

Topalian SL, Rosenberg SA.

Important Adv Oncol. 1990:19-41. Review. No abstract available.

PMID:
2182519
12.

Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Greenberg PD.

Adv Immunol. 1991;49:281-355. Review. No abstract available.

PMID:
1853786
13.

The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Ettinghausen SE, Rosenberg SA.

Springer Semin Immunopathol. 1986;9(1):51-71. Review. No abstract available.

PMID:
3523804
15.

Chemical xenogenization: antigenic changes of cancer cells induced by triazene compounds.

Giuliani A, D'Atri S, Franchi A, Tricarico M, Tentori L, Bonmassar E.

Contrib Gynecol Obstet. 1991;18:79-92. Review. No abstract available.

PMID:
1718661
16.

The role of tumor rejection antigens in host antitumor defense mechanisms.

Campbell FA, Redmond HP, Bouchier-Hayes D.

Cancer. 1995 Jun 1;75(11):2649-55. Review.

17.

Immunological intervention in neoplasia.

Weiss DW.

Johns Hopkins Med J Suppl. 1974;3:131-56. Review. No abstract available.

PMID:
4371312
18.

Manipulation of host resistance in cancer therapy.

Baldwin RW.

Springer Semin Immunopathol. 1982;5(2):113-25. Review. No abstract available.

PMID:
6755781
19.

Cancer immunotherapy with autologous and allogeneic vaccines: a practical overview.

Shinitzky M, Skornick Y.

Prog Clin Biol Res. 1990;348:95-125. Review. No abstract available.

PMID:
2201036
20.

[A new approach to immunotherapy of cancer based on autologous T-lymphocytes].

Dosne Pasqualini C, Laguens RP.

Medicina (B Aires). 1987;47(3):307-12. Review. Spanish. No abstract available.

PMID:
3326997
Items per page

Supplemental Content

Write to the Help Desk